文献速递消化系统肿瘤

肝细胞癌外照射放疗总生存:跨国队列个体患者数据分析

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
PubMed 文献 · J Clin Oncol · 2026-05-15

该研究系统检索并汇总跨国队列个体患者数据,分析接受外照射放疗(EBRT)的肝细胞癌(HCC)患者总生存(OS)。共纳入4913例患者,中位随访5.0年;BCLC-0期和A期的中位OS分别为6.8年和4.6年,初治患者BCLC-0期未达到、BCLC-A期为5.4年。结论认为EBRT对极早期和早期HCC的OS与切除、热消融等相当,支持将EBRT纳入BCLC决策流程。

要点

  • BCLC-0期HCC接受EBRT的中位OS为6.8年(95%CI 5.7–8.7)。
  • BCLC-A期初治患者接受EBRT的中位OS为5.4年(95%CI 4.5–6.7)。
  • 更晚BCLC分期、更高肿瘤负荷、更差体能状态及Child-Pugh B/C与死亡风险升高相关。

核心结论

  • EBRT治疗极早期和早期HCC的OS与切除、热消融及其他消融性局部治疗相当,支持将EBRT纳入BCLC决策流程。

研究设计与样本

  • 共纳入4913例接受EBRT的HCC患者,中位随访5.0年。
  • 采用Kaplan-Meier法按BCLC分期和治疗状态分层分析OS和限制性平均生存时间(RMST),并用随机效应Cox比例风险模型评估与OS相关的临床特征。

主要发现

  • BCLC-0期患者中位OS为6.8年(95%CI 5.7–8.7),BCLC-A期为4.6年(95%CI 4.1–5.1)。
  • 初治患者中,BCLC-0期中位OS未达到(95%CI 8.6–未达到),BCLC-A期为5.4年(95%CI 4.5–6.7)。
  • 多因素模型中,更晚BCLC分期、更高肿瘤负荷、更差体能状态及Child-Pugh B或C级与死亡风险升高相关。
  • 消融性放疗剂量和更近的治疗年份与死亡风险降低相关。

临床怎么用

  • 对于极早期和早期HCC,EBRT可作为与切除、热消融等局部治疗相当的生存选择。
  • 临床决策中可将EBRT纳入BCLC分期系统的治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given limited evidence that it improves overall survival (OS). We analyzed individual patient data (IPD) from an international cohort to assess OS among patients with HCC treated with EBRT. METHODS: We performed a systematic review of publications that assessed EBRT, met prespecified technical standards for HCC, and reported OS (search date December 15, 2022). Corresponding authors were invited to submit IPD for the study. We performed Kaplan-Meier survival analyses to determine OS and restricted mean survival time (RMST) stratified by Barcelona Clinic Liver Cancer (BCLC) stage and treatment status (ie, treatment-naïve and experienced). We performed random effects Cox proportional hazards modeling to assess clinical characteristics associated with OS. RESULTS: Data were provided on 4,913 patients treated with EBRT with a median follow-up time of 5.0 years. The median OS was 6.8 years (95% CI, 5.7 to 8.7) for BCLC-0 and 4.6 years (95% CI, 4.1 to 5.1) for BCLC-A. Among treatment-naïve patients, the median OS was not reached (95% CI, 8.6 to not reached) for BCLC-0 and was 5.4 years (95% CI, 4.5 to 6.7) for BCLC-A. In multivariable models, more advanced BCLC stage, higher tumor burden, worse performance status, and Child-Pugh class B or C were associated with a higher risk of mortality. Ablative radiation dose and more recent year of treatment were associated with a reduced risk of death. CONCLUSION: To our knowledge, this study represents the largest multinational cohort of patients with HCC treated with EBRT. OS outcomes with EBRT for very early- and early-stage HCC appear to be comparable with resection, thermal ablation, and other ablative locoregional therapies. These data support the inclusion of EBRT in the BCLC HCC clinical decision-making process.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Moon AM, Yanagihara TK, Dawson LA, et al. Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort. J Clin Oncol. 2026. PMID: 42139645. doi:10.1200/JCO-25-02399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。